bpc 157 fda warning letter unapproved peptide Public advisory FDA to Revisit Peptide Compounding
Description
These questions arise in part from social-media-driven interest in the compound and in part from what limited early data exist
Kreugel G, Beijer H, Kerstens M, Ter Maaten J, Sluiter W, Boot B

Lets explore each of them
They validated their findings with subsequent real-world data from Ontario and Connecticut

A study in the Journal of Clinical Endocrinology and Metabolism (online, Feb
